Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.

BACKGROUND Amyloid-β (Aβ) accumulation in brain of patients with suspected Alzheimer's disease (AD) can be assessed by positron emission tomography (PET) in vivo. While visual classification prevails in the clinical routine, semiquantitative PET analyses may enable more reliable evaluation of cases with a visually uncertain, borderline Aβ accumulation. OBJECTIVE We evaluated different analysis approaches (visual/semiquantitative) to find the most accurate and sensitive interpretation of Aβ-PET for predicting risk of progression from mild cognitive impairment (MCI) to AD. METHODS Based on standard uptake value (SUV) ratios of a cortical-composite volume of interest of 18F-AV45-PET from MCI subjects (n = 396, ADNI database), we compared three different reference region (cerebellar grey matter, CBL; brainstem, BST; white matter, WM) normalizations and the visual read by receiver operator characteristics for calculating a hazard ratio (HR) for progression to Alzheimer's disease dementia (ADD). RESULTS During a mean follow-up time of 45.6±13.0 months, 28% of the MCI cases (110/396) converted to ADD. Among the tested methods, the WM reference showed best discriminatory power and progression-risk stratification (HRWM of 4.4 [2.6-7.6]), but the combined results of the visual and semiquantitative analysis with all three reference regions showed an even higher discriminatory power. CONCLUSION A multi-analytical composite of visual and semiquantitative reference tissue analyses of 18F-AV45-PET gave improved risk stratification for progression from MCI to ADD relative to performance of single read-outs. This optimized approach is of special interest for prospective treatment trials, which demand a high accuracy.

[1]  P. Malhotra,et al.  Optimisation and usefulness of quantitative analysis of 18F-florbetapir PET. , 2019, The British journal of radiology.

[2]  A. Chincarini,et al.  Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC) , 2019, NeuroImage: Clinical.

[3]  H. Struyfs,et al.  Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging , 2019, NeuroImage: Clinical.

[4]  V. Grau,et al.  Classification of amyloid PET images using novel features for early diagnosis of Alzheimer’s disease and mild cognitive impairment conversion , 2019, Nuclear medicine communications.

[5]  Sterling C. Johnson,et al.  Predicting Alzheimer’s disease progression using multi-modal deep learning approach , 2019, Scientific Reports.

[6]  C. Jack,et al.  Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers , 2017, The Lancet Neurology.

[7]  C. Jack,et al.  Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework , 2017, Neurobiology of Aging.

[8]  J. Seibyl,et al.  Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  P. Pasqualetti,et al.  Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. , 2016, JAMA neurology.

[10]  A. Villringer,et al.  Feasibility and acceptance of simultaneous amyloid PET/MRI , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  S. Shokouhi,et al.  Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment , 2016, Alzheimer's Research & Therapy.

[12]  Stefanie Schreiber,et al.  Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. , 2015, JAMA neurology.

[13]  I. Choo,et al.  Structural MRI and Amyloid PET Imaging for Prediction of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis , 2015, Alzheimer's & Dementia.

[14]  William J. Jagust,et al.  Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.

[15]  Daniel Bandy,et al.  Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region , 2015, The Journal of Nuclear Medicine.

[16]  John Seibyl,et al.  Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.

[17]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[18]  Keith A. Johnson,et al.  Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.

[19]  Rik Ossenkoppele,et al.  Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.

[20]  C. Bottino,et al.  Correlation of brain structural and functional changes in amnestic mild cognitive impairment and mild Alzheimer's disease: A voxel-by-voxel analysis in a single cohort of patients in Brazil , 2013, Alzheimer's & Dementia.

[21]  M. Viitanen,et al.  [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[23]  M. Mintun,et al.  Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline , 2013, Alzheimer disease and associated disorders.

[24]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[25]  J O Rinne,et al.  Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.

[26]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[27]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[28]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[29]  Anders M. Dale,et al.  Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.

[30]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[31]  Alexander Hammers,et al.  Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.

[32]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[33]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[34]  T. Werner,et al.  18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis. , 2019, Journal of Alzheimer's disease : JAD.

[35]  C. Jack,et al.  Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 9-19-17 3 4 5 , 2017 .

[36]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.